Aclaris Therapeutics Inc. (ACRS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Aclaris Therapeutics Inc. (ACRS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.50

0.02 (0.81%)

At close: Jan 14, 2025, 3:59 PM

2.51

0.60%

After-hours Jan 14, 2025, 04:41 PM EST

undefined% (undefined)

Bid	2.51
Market Cap	267.01M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.52
PE Ratio (ttm)	-4.8
Forward PE	n/a
Analyst	Buy

Ask	2.58
Volume	2,592,429
Avg. Volume (20D)	2,587,559
Open	2.50
Previous Close	2.48
Day's Range	2.31 - 2.50
52-Week Range	0.95 - 5.17
Beta	undefined

About ACRS

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Oct 6, 2015

Employees 86

Stock Exchange NASDAQ

Ticker Symbol ACRS

Website https://www.aclaristx.com

Analyst Forecast

According to 5 analyst ratings, the average rating for ACRS stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 220.64% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Aclaris Therapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $5.85M, reflecting a -66.7% YoY shrinking and earnings per share of -0.27, making a -10.00% decrease YoY.

Why Price Moved

1 month ago · Source

+46.18%

Aclaris Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

1 month ago · Source

+53.17%

Aclaris Therapeutics shares are trading higher after the company announced it entered into an exclusive license agreement with Biosion for worldwide rights to BSI-045B. The company announced an $80 million private placement.

News

3 weeks ago · benzinga.com

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

HC Wainwright & Co. analyst Raghuram Selvaraju upgraded Aclaris Therapeutics Inc ACRS from Neutral to Buy and a price target of $20. The stock gained after the rerating.

1 month ago · benzinga.com

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

On Monday, Aclaris Therapeutics, Inc. ACRS entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, no...

1 month ago · zacks.com

ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs

Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.

2 months ago · zacks.com

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.41 per share a year ago.